Parkinson’s Disease: How to Read the Evidence on the Gut–Brain Axis, Risk Signals, and Treatment

The Full Evidence Picture for Parkinson’s Disease

The conclusion in one sentence

Parkinson’s disease is a neurodegenerative disorder centered on abnormal α-synuclein aggregation and potentially influenced by multiple factors, including the gut–brain axis. Associations involving the gut, diet, or environmental risks cannot, on their own, be rewritten as the “true culprit” or as proof that a given individual will inevitably develop the disease. PMID: 42154337

Why “the culprit lies in the gut” goes too far

In his original article, Professor Ching-Shun Lin addressed media reports that recast a mouse study as proof that “the true culprit in Parkinson’s disease is not the brain but the gut.” He noted that gut microbes triggered or worsened motor deficits only in mice engineered to overexpress α-synuclein. The study demonstrated a regulatory effect; it did not show that the microbiota can independently cause Parkinson’s disease in an otherwise typical individual. This interpretation faithfully reflects the original paper: the abnormal α-synuclein background was an essential condition of the experiment, and a mouse model cannot be translated directly into a cause of human disease. PMID: 27912057

As the science has advanced, the role of the gut has indeed become more important than early evidence suggested. Alterations in the gut microbiota are common among people with Parkinson’s disease, but finding that “patients differ from healthy people” remains an association; it does not mean that a single cause has been identified. PMID: 42302222

Newer research continues to investigate whether α-synuclein pathology might begin in the enteric nervous system and spread to the brain along neural pathways. This work makes the gut a plausible participant in early disease processes and a potential therapeutic target. PMID: 40362234

Viewed in light of today’s literature, Professor Lin’s central position remains sound: sensational headlines should be challenged, and results from animal studies should not be applied directly to humans. What needs updating is the idea that the gut can be dismissed as an unimportant downstream phenomenon. It may participate in upstream or early processes, but the evidence still does not justify declaring that “gut microbes are the culprit.” Strategies such as fecal microbiota transplantation likewise remain investigational. PMID: 42533232

Core pathology and treatable symptoms

Abnormally folded and aggregated α-synuclein is an important feature of Parkinson’s disease and one of the central elements in current understanding of its pathological mechanisms. PMID: 42218352

Clinical care must distinguish between “improving symptoms” and “changing the course of disease.” Levodopa remains a principal and effective symptomatic treatment, but disease progression and changes in pharmacokinetics can lead some patients to experience wearing-off periods or motor fluctuations. PMID: 29670409

Safinamide is a monoamine oxidase B inhibitor that can be used as add-on therapy to levodopa to help manage motor fluctuations. Whether it is appropriate, and whether it can be combined with other medicines, must be assessed by a physician in light of liver function, the patient’s medication regimen, and potential interactions. PMID: 40055961

Regarding the claim that “levodopa makes nerve cells degenerate faster,” the clinical and imaging findings from randomized trials have permitted different interpretations. There is no conclusive proof that levodopa accelerates neurodegeneration. PMID: 15590952

At the same time, limited data should not be expanded into an absolute guarantee of “zero neurotoxicity.” Available follow-up evidence more strongly supports the conclusion that progression of clinical symptoms does not differ substantially among oral levodopa formulations. PMID: 33538517

Diet and environment: an association is not a cause

Prospective cohort research has reported a modest association between the consumption of low-fat dairy products—particularly low-fat or skim milk—and the risk of Parkinson’s disease. The study followed participants using questionnaires; it was not a trial that randomly assigned people to drink milk to see whether it caused disease. PMID: 28596209

Subsequent pooled evidence is still based on observational studies. The reasonable conclusion is therefore that “an association signal exists,” not that “low-fat milk causes Parkinson’s disease.” The evidence is also insufficient to justify a universal recommendation to avoid dairy products. PMID: 41544344

Pesticide exposure has likewise been associated observationally with an increased risk of Parkinson’s disease, but the quality of the evidence and the study findings remain limited or inconsistent. Not every pesticide exposure can be treated as an established cause. PMID: 40243837

A case-control study of people living near golf courses or within associated water-service areas reported an association with risk. The investigators proposed drinking-water contamination as a possible route, but they did not directly measure each person’s pesticide exposure and did not establish that groundwater contamination caused the disease. PMID: 40338549

Similarly, observational findings on iron in the brain and cognitive change cannot be rewritten as evidence that “iron in an ordinary diet causes Parkinson’s disease.” A causal judgment about any single food or nutrient requires human evidence more direct than correlation. PMID: 30778133

Prodromal signals are not predictions of destiny

A reduced sense of smell is associated with a higher subsequent risk of Parkinson’s disease and can serve as a short- or medium-term risk signal. Poor olfaction, however, has many causes. A single test cannot establish the diagnosis or predict that a particular person will inevitably develop the disease. PMID: 28878051

Diagnosed isolated or idiopathic rapid eye movement sleep behavior disorder is an important prodromal risk marker for Parkinson’s disease, dementia with Lewy bodies, and other synucleinopathies. Even so, “high risk” does not mean that an individual will inevitably convert to one of these conditions. PMID: 30789229

Management of this type of sleep disorder begins with reducing the risk of injury at night. Medication should be selected by a clinician according to the individual’s circumstances; melatonin and clonazepam are among the options listed in clinical guidance. PMID: 36515157

For trazodone, the current signal is limited to case-level evidence. That is not enough to support its general use as a treatment that can replace standard management. PMID: 38156419

Supplements and new therapies: a signal is not proof of efficacy

Clinical findings for hydrogen-rich water in Parkinson’s disease remain mixed. Existing evidence is insufficient to show that hydrogen-rich water alone improves the disease. PMID: 40336538

An early human study combining hydrogen-rich water with photobiomodulation reported improvement on some symptom scales, but it could not isolate the effect of the water itself. The findings do not justify claims of a cure, restored walking ability, or a change in the course of disease. PMID: 33530211

Native oral glutathione has very low gastrointestinal bioavailability, and there is insufficient human evidence to establish the claim that taking it orally can prevent Parkinson’s disease. PMID: 36117769

Nervonic acid has shown a protective signal in an animal model of ischemia–reperfusion, but this does not directly demonstrate that damaged human nerves can be repaired. Animal findings are a starting point for research, not the endpoint for evidence of efficacy in humans. PMID: 38566522

A practical position to take now

No therapy has yet been proven to prevent Parkinson’s disease or definitively slow its course. Risk associations, animal mechanisms, small uncontrolled studies, and product marketing therefore should not be treated as medical promises. PMID: 31792092

Anyone who develops slowness of movement, tremor, rigidity, a change in smell, or dream-enactment behavior should be evaluated by a neurology or sleep specialist. They should not independently stop levodopa, eliminate dairy products, purchase expensive supplements, or try unestablished therapies. At present, the most reliable approach to decision-making is to distinguish the evidentiary thresholds for symptomatic treatment, risk markers, and disease modification, and then make decisions jointly on the basis of the individual diagnosis and medication risks. PMID: 40055961